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In a recent article published in CancerShui et al. observed no statistically significant relationship 
between circulating 25-hydroxyvitamin D (25(OH)D) and fatal prostate cancer (PCa)1. However, an 
association between CYP2R1 SNPs and fatal PCa is found1. CYP2R1 is the hydroxylase involved in the 
conversion of vitamin D into 25(OH)D. In the classical vitamin D endocrine system,activation of 
vitamin D into 1,25(OH)2D requires two successive hydroxylation steps. The first one is catalyzed by 
CYP2R1 in the liver and the second one by CYP27B1 in the kidneys. Then, 1,25D is released in the 
blood circulation and behaves as an endocrine hormone. The conversion of 25(OH)Dinto the active 
hormone 1,25(OH)2D by CYP27B1 is under stringent control. However, the first hydroxylation step 
catalyzed in the liver by CYP2R1 is constitutive and is not believed to be subjected to tight regulation. 
This has two important consequences: i) the regulation of liver CYP2R1  has retained little attention, 
and ii) circulating non-hydroxylated vitamin D is rapidly metabolized by liver CYP2R1. Therefore, 
25(OH)D concentrations are considered to reflect vitamin D inputsand are used to determine the 
vitamin D status.  
A major breakthrough in our understanding on the nonskeletal effects of vitamin D is the recent 
discovery of autocrine/paracrine vitamin D systemsin many tissues2.This autocrine/paracrine 
signalingensures the local bioactivation of 25(OH)D into 1,25(OH)2D by extra-renal CYP27B1. In 
autocrine/paracrine vitamin D systems, the vitamin D metabolites are produced, act and are 
degraded locally without affecting serum 25(OH)D levels. Shui and coll rightly pointed out that local 
synthesis of 1,25(OH)2D from 25(OH)D can occur,because CYP27B1 is expressed in the prostate. 
However, the authors do not mention that CYP2R1 is also expressed in prostate tissue3. The fact that 
prostate can also perform the conversion of vitamin D into 25(OH)D is critical. Activity of prostate 
CYP2R1 depends on the local bio-availability of its substrate, namelynon-hydroxylated vitamin D. 
There is very little circulating non-hydroxylated vitamin D in the body, but storage can occur. 
Thisrequires large inputs and is mainly observed in fat tissues whencirculating 25(OH)D 
concentrations exceed 90 nmol/L4. This value is higher than the defined physiological levels for 
25(OH)D sufficiency (50 nmol/L -75 nmol/L) but is consistent with 25(OH)D concentrations suggested 
to reduce cancer risk (150 nmol/L)5. The existence of a functional vitamin D autocrine/paracrine 
system in prostate that depends on the local bio-availability of non-hydroxylated vitamin D explains 
the findings reported by Shiu et al. that are:i) the lack of significant association between circulating 
25(OH)D and fatal Pca, and ii) the association between CYP2R1 SNPs and fatal PCa.CYP2R1 and 
CYP27B1 expression are regulated by inflammatory stimuli6. In the prostate cancer inflammatory 
microenvironment, locally bioavailable non-hydroxylated vitamin D would be metabolized first by 
prostate CYP2R1 to generate 25(OH)D and then by CYP27B1 to produce 1,25(OH)D. This prostate 
autocrine/paracrine vitamin D system is disconnected to the physiological circulating levels of 
25(OH)D (50-75 nmol/L) but will depend on local stores of non-hydroxylated vitamin D and of CYP2R1 
activity. The co-existence of two vitamin D systems (endocrine and autocrine/paracrine) with 
different aims and characteristics, including optimal vitamin D requirements, enlightens the 
complexity of the vitamin D functions. The association between CYP2R1 SNPs and fatal PCa described 
by Shui et al points to the importance to include analyses on the bioavailability ofnon-
hydroxylatedvitamin D in studies investigating relationships between vitamin D and cancer.  
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